Dr. Reddy’s Laboratories Ltd. hopes to derail a patent on Indivior Plc’s top-selling opioid treatment Suboxone.
The Indian generic company is asking the Patent and Trademark Office’s Patent Trial and Appeal Board to review an Indivior patent that’s blocking Dr. Reddy’s from entering the U.S. market with a copy of the film version of the drug. Suboxone film is placed under the tongue and is considered easier to use than suboxone tablets or injected treatments. Dr. Reddy’s has filed two separate petitions with the board challenging the patent’s claims on the grounds they are obvious or anticipated by prior art. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.